Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

A Functional Idiotype/Anti-Idiotype Network Is Active in Genetically Gluten-Intolerant Individuals Negative for Both Celiac Disease-Related Intestinal Damage and Serum Autoantibodies.

Quaglia S, Ferrara F, De Leo L, Ziberna F, Vatta S, Marchiò S, Sblattero D, Ventura A, Not T.

J Immunol. 2019 Feb 15;202(4):1079-1087. doi: 10.4049/jimmunol.1800819. Epub 2019 Jan 11.

PMID:
30635394
2.

Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions.

Crane ED, Al-Hashimi AA, Chen J, Lynn EG, Won KD, Lhoták Š, Naeim M, Platko K, Lebeau P, Byun JH, Shayegan B, Krepinsky JC, Rayner KJ, Marchiò S, Pasqualini R, Arap W, Austin RC.

JCI Insight. 2018 Dec 20;3(24). pii: 99363. doi: 10.1172/jci.insight.99363.

3.

Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review.

Chohan MO, Marchiò S, Morrison LA, Sidman RL, Cavenee WK, Dejana E, Yonas H, Pasqualini R, Arap W.

JAMA Neurol. 2018 Nov 26. doi: 10.1001/jamaneurol.2018.3634. [Epub ahead of print]

PMID:
30476961
4.

Pressure control in interfacial systems: Atomistic simulations of vapor nucleation.

Marchio S, Meloni S, Giacomello A, Valeriani C, Casciola CM.

J Chem Phys. 2018 Feb 14;148(6):064706. doi: 10.1063/1.5011106.

PMID:
29448782
5.

Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

Staquicini DI, D'Angelo S, Ferrara F, Karjalainen K, Sharma G, Smith TL, Tarleton CA, Jaalouk DE, Kuniyasu A, Baze WB, Chaffee BK, Hanley PW, Barnhart KF, Koivunen E, Marchiò S, Sidman RL, Cortes JE, Kantarjian HM, Arap W, Pasqualini R.

Pharmacogenomics J. 2018 May 22;18(3):436-443. doi: 10.1038/tpj.2017.46. Epub 2017 Dec 5.

PMID:
29205207
6.

Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor.

Al-Hashimi AA, Lebeau P, Majeed F, Polena E, Lhotak Š, Collins CAF, Pinthus JH, Gonzalez-Gronow M, Hoogenes J, Pizzo SV, Crowther M, Kapoor A, Rak J, Gyulay G, D'Angelo S, Marchiò S, Pasqualini R, Arap W, Shayegan B, Austin RC.

J Biol Chem. 2017 Dec 22;292(51):21180-21192. doi: 10.1074/jbc.M117.799908. Epub 2017 Oct 24.

7.

Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses.

Teixeira AA, Marchiò S, Dias-Neto E, Nunes DN, da Silva IT, Chackerian B, Barry M, Lauer RC, Giordano RJ, Sidman RL, Wheeler CM, Cavenee WK, Pasqualini R, Arap W.

EMBO Mol Med. 2017 Oct;9(10):1327-1330. doi: 10.15252/emmm.201708072. No abstract available.

8.

BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.

Lewis VO, Devarajan E, Cardó-Vila M, Thomas DG, Kleinerman ES, Marchiò S, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8065-8070. doi: 10.1073/pnas.1704173114. Epub 2017 Jul 11.

9.

Intracellular targeting of annexin A2 inhibits tumor cell adhesion, migration, and in vivo grafting.

Staquicini DI, Rangel R, Guzman-Rojas L, Staquicini FI, Dobroff AS, Tarleton CA, Ozbun MA, Kolonin MG, Gelovani JG, Marchiò S, Sidman RL, Hajjar KA, Arap W, Pasqualini R.

Sci Rep. 2017 Jun 26;7(1):4243. doi: 10.1038/s41598-017-03470-w.

10.

Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone.

Kolonin MG, Sergeeva A, Staquicini DI, Smith TL, Tarleton CA, Molldrem JJ, Sidman RL, Marchiò S, Pasqualini R, Arap W.

Cancer Res. 2017 Jun 15;77(12):3144-3150. doi: 10.1158/0008-5472.CAN-16-0708. Epub 2017 Apr 20.

11.

An antivascular vaccine to boost self-immunity and strike the tumor.

Marchiò S, Bansal P, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3164-E3165. doi: 10.1073/pnas.1701452114. Epub 2017 Apr 11. No abstract available.

12.

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.

Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG 2nd, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12786-12791. doi: 10.1073/pnas.1615400113. Epub 2016 Oct 24.

13.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12780-12785. doi: 10.1073/pnas.1615288113. Epub 2016 Oct 24.

14.

Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity.

Cardó-Vila M, Marchiò S, Sato M, Staquicini FI, Smith TL, Bronk JK, Yin G, Zurita AJ, Sun M, Behrens C, Sidman RL, Lee JJ, Hong WK, Wistuba II, Arap W, Pasqualini R.

Am J Pathol. 2016 Aug;186(8):2162-2170. doi: 10.1016/j.ajpath.2016.04.013. Epub 2016 Jun 16.

15.

Brain endothelial cell-targeted gene therapy of neurovascular disorders.

Marchiò S, Sidman RL, Arap W, Pasqualini R.

EMBO Mol Med. 2016 Jun 1;8(6):592-4. doi: 10.15252/emmm.201606407. Print 2016 Jun. No abstract available.

16.

BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer.

Bartolini A, Cardaci S, Lamba S, Oddo D, Marchiò C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, Pasqualini R, Arap W, Corà D, Di Nicolantonio F, Marchiò S.

Clin Cancer Res. 2016 Oct 1;22(19):4923-4933. Epub 2016 May 3.

17.

Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors.

Dondossola E, Dobroff AS, Marchiò S, Cardó-Vila M, Hosoya H, Libutti SK, Corti A, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2223-8. doi: 10.1073/pnas.1525697113. Epub 2016 Feb 8.

18.

Ligand-targeted theranostic nanomedicines against cancer.

Yao VJ, D'Angelo S, Butler KS, Theron C, Smith TL, Marchiò S, Gelovani JG, Sidman RL, Dobroff AS, Brinker CJ, Bradbury ARM, Arap W, Pasqualini R.

J Control Release. 2016 Oct 28;240:267-286. doi: 10.1016/j.jconrel.2016.01.002. Epub 2016 Jan 6. Review.

19.

The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients.

Bartolini A, Di Paolo D, Noghero A, Murgia D, Sementa AR, Cilli M, Pasqualini R, Arap W, Bussolino F, Ponzoni M, Pastorino F, Marchiò S.

Cancer Res. 2015 Oct 15;75(20):4265-71. doi: 10.1158/0008-5472.CAN-15-0649. Epub 2015 Aug 20.

20.

Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.

Cossu I, Bottoni G, Loi M, Emionite L, Bartolini A, Di Paolo D, Brignole C, Piaggio F, Perri P, Sacchi A, Curnis F, Gagliani MC, Bruno S, Marini C, Gori A, Longhi R, Murgia D, Sementa AR, Cilli M, Tacchetti C, Corti A, Sambuceti G, Marchiò S, Ponzoni M, Pastorino F.

Biomaterials. 2015 Nov;68:89-99. doi: 10.1016/j.biomaterials.2015.07.054. Epub 2015 Aug 1.

21.

PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8403-8. doi: 10.1073/pnas.1507882112. Epub 2015 Jun 15.

22.

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.

Pignochino Y, Dell'Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, Canta M, Piloni D, Cemmi F, Sangiolo D, Gammaitoni L, Soster M, Marchiò S, Pozzi E, Morbini P, Luisetti M, Aglietta M, Grignani G, Stella GM.

BMC Cancer. 2015 May 8;15:374. doi: 10.1186/s12885-015-1363-1.

23.

Synchronous down-modulation of miR-17 family members is an early causative event in the retinal angiogenic switch.

Nunes DN, Dias-Neto E, Cardó-Vila M, Edwards JK, Dobroff AS, Giordano RJ, Mandelin J, Brentani HP, Hasselgren C, Yao VJ, Marchiò S, Pereira CA, Passetti F, Calin GA, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3770-5. doi: 10.1073/pnas.1500008112. Epub 2015 Mar 9.

24.

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.

Peraldo-Neia C, Cavalloni G, Soster M, Gammaitoni L, Marchiò S, Sassi F, Trusolino L, Bertotti A, Medico E, Capussotti L, Aglietta M, Leone F.

BMC Cancer. 2014 Dec 5;14:918. doi: 10.1186/1471-2407-14-918.

25.

Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer.

Parri M, Pietrovito L, Grandi A, Campagnoli S, De Camilli E, Bianchini F, Marchiò S, Bussolino F, Jin B, Sarmientos P, Grandi G, Viale G, Pileri P, Chiarugi P, Grifantini R.

Angiogenesis. 2014 Oct;17(4):881-96. doi: 10.1007/s10456-014-9435-4. Epub 2014 Jun 6.

PMID:
24903490
26.

The V1/V2 loop of HIV-1 gp120 is necessary for Tat binding and consequent modulation of virus entry.

Cardaci S, Soster M, Bussolino F, Marchiò S.

FEBS Lett. 2013 Sep 17;587(18):2943-51. doi: 10.1016/j.febslet.2013.07.039. Epub 2013 Jul 31.

27.

Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.

Loi M, Di Paolo D, Soster M, Brignole C, Bartolini A, Emionite L, Sun J, Becherini P, Curnis F, Petretto A, Sani M, Gori A, Milanese M, Gambini C, Longhi R, Cilli M, Allen TM, Bussolino F, Arap W, Pasqualini R, Corti A, Ponzoni M, Marchiò S, Pastorino F.

J Control Release. 2013 Sep 10;170(2):233-41. doi: 10.1016/j.jconrel.2013.04.029. Epub 2013 May 25.

28.

A peptide from the extracellular region of the synaptic protein α Neurexin stimulates angiogenesis and the vascular specific tyrosine kinase Tie2.

Graziano S, Marchiò S, Bussolino F, Arese M.

Biochem Biophys Res Commun. 2013 Mar 22;432(4):574-9. doi: 10.1016/j.bbrc.2013.02.045. Epub 2013 Feb 26.

29.

Luminescent silica nanoparticles for cancer diagnosis.

Arap W, Pasqualini R, Montalti M, Petrizza L, Prodi L, Rampazzo E, Zaccheroni N, Marchiò S.

Curr Med Chem. 2013;20(17):2195-211. Review.

30.

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

Pignochino Y, Dell'Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D, Torchiaro E, D'Ambrosio L, Fagioli F, Ferrari S, Alberghini M, Picci P, Aglietta M, Grignani G.

Clin Cancer Res. 2013 Apr 15;19(8):2117-31. doi: 10.1158/1078-0432.CCR-12-2293. Epub 2013 Feb 22.

31.

Emerging lymphae for the fountain of life.

Marchiò S, Astanina E, Bussolino F.

EMBO J. 2013 Mar 6;32(5):609-11. doi: 10.1038/emboj.2013.13. Epub 2013 Jan 29.

32.

A complex of α6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6.

Marchiò S, Soster M, Cardaci S, Muratore A, Bartolini A, Barone V, Ribero D, Monti M, Bovino P, Sun J, Giavazzi R, Asioli S, Cassoni P, Capussotti L, Pucci P, Bugatti A, Rusnati M, Pasqualini R, Arap W, Bussolino F.

EMBO Mol Med. 2012 Nov;4(11):1156-75. doi: 10.1002/emmm.201101164. Epub 2012 Oct 16.

33.

Targeted dual-color silica nanoparticles provide univocal identification of micrometastases in preclinical models of colorectal cancer.

Soster M, Juris R, Bonacchi S, Genovese D, Montalti M, Rampazzo E, Zaccheroni N, Garagnani P, Bussolino F, Prodi L, Marchiò S.

Int J Nanomedicine. 2012;7:4797-807. doi: 10.2147/IJN.S33825. Epub 2012 Sep 5.

34.

IL-12-dependent innate immunity arrests endothelial cells in G0-G1 phase by a p21(Cip1/Waf1)-mediated mechanism.

Napione L, Strasly M, Meda C, Mitola S, Alvaro M, Doronzo G, Marchiò S, Giraudo E, Primo L, Arese M, Bussolino F.

Angiogenesis. 2012 Dec;15(4):713-25. doi: 10.1007/s10456-012-9286-9. Epub 2012 Jul 15.

PMID:
22797886
35.

Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.

Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, Marchiò S, Aglietta M, Leone F.

Mol Cancer Ther. 2012 Jul;11(7):1528-38. doi: 10.1158/1535-7163.MCT-11-1020. Epub 2012 Mar 27.

36.

Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.

Loi M, Marchiò S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, Longhi R, Nico B, Bussolino F, Gambini C, Ribatti D, Cilli M, Arap W, Pasqualini R, Allen TM, Corti A, Ponzoni M, Pastorino F.

J Control Release. 2010 Jul 1;145(1):66-73. doi: 10.1016/j.jconrel.2010.03.015. Epub 2010 Mar 24.

PMID:
20346382
37.

Targeting the extracellular signature of metastatic colorectal cancers.

Marchiò S, Arap W, Pasqualini R.

Expert Opin Ther Targets. 2009 Mar;13(3):363-79. doi: 10.1517/14728220902762910 . Review.

PMID:
19236157
38.

A new computational approach to analyze human protein complexes and predict novel protein interactions.

Zanivan S, Cascone I, Peyron C, Molineris I, Marchio S, Caselle M, Bussolino F.

Genome Biol. 2007;8(12):R256.

39.

Identification of CD36 molecular features required for its in vitro angiostatic activity.

Primo L, Ferrandi C, Roca C, Marchiò S, di Blasio L, Alessio M, Bussolino F.

FASEB J. 2005 Oct;19(12):1713-5. Epub 2005 Jul 21.

PMID:
16037098
40.

Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein.

Marchiò S, Alfano M, Primo L, Gramaglia D, Butini L, Gennero L, De Vivo E, Arap W, Giacca M, Pasqualini R, Bussolino F.

Blood. 2005 Apr 1;105(7):2802-11. Epub 2004 Dec 9.

41.

Aminopeptidase A is a functional target in angiogenic blood vessels.

Marchiò S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, Hajitou A, Ozawa MG, Trepel M, Giordano RJ, Nanus DM, Dijkman HB, Oosterwijk E, Sidman RL, Cooper MD, Bussolino F, Pasqualini R, Arap W.

Cancer Cell. 2004 Feb;5(2):151-62.

42.

Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells.

Marchiò S, Primo L, Pagano M, Palestro G, Albini A, Veikkola T, Cascone I, Alitalo K, Bussolino F.

J Biol Chem. 1999 Sep 24;274(39):27617-22.

43.

c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro.

Marconcini L, Marchio S, Morbidelli L, Cartocci E, Albini A, Ziche M, Bussolino F, Oliviero S.

Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9671-6.

44.

Overexpression of the RON gene in human breast carcinoma.

Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM.

Oncogene. 1998 Jun 4;16(22):2927-33.

Supplemental Content

Loading ...
Support Center